210 related articles for article (PubMed ID: 28176349)
1. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.
Cadier B; Bulsei J; Nahon P; Seror O; Laurent A; Rosa I; Layese R; Costentin C; Cagnot C; Durand-Zaleski I; Chevreul K;
Hepatology; 2017 Apr; 65(4):1237-1248. PubMed ID: 28176349
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
[TBL] [Abstract][Full Text] [Related]
3. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?
Landman MP; Feurer ID; Pinson CW; Moore DE
HPB (Oxford); 2011 Nov; 13(11):783-91. PubMed ID: 21999591
[TBL] [Abstract][Full Text] [Related]
4. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.
Lim KC; Wang VW; Siddiqui FJ; Shi L; Chan ES; Oh HC; Tan SB; Chow PK
Hepatology; 2015 Jan; 61(1):227-37. PubMed ID: 24638991
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.
Thein HH; Isaranuwatchai W; Qiao Y; Wong K; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
Cancer Med; 2017 Sep; 6(9):2017-2033. PubMed ID: 28791798
[TBL] [Abstract][Full Text] [Related]
7. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.
Spolverato G; Vitale A; Ejaz A; Kim Y; Maithel SK; Cosgrove DP; Pawlik TM
World J Surg; 2015 Jun; 39(6):1474-84. PubMed ID: 25665675
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
9. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
[TBL] [Abstract][Full Text] [Related]
10. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma.
Naugler WE; Sonnenberg A
Liver Transpl; 2010 Oct; 16(10):1186-94. PubMed ID: 20879017
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.
Kuo MJ; Chen HH; Chen CL; Fann JC; Chen SL; Chiu SY; Lin YM; Liao CS; Chang HC; Lin YS; Yen AM
World J Gastroenterol; 2016 Mar; 22(12):3460-70. PubMed ID: 27022228
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.
Xie L; Yin J; Xia R; Zhuang G
Hepatology; 2018 Oct; 68(4):1476-1486. PubMed ID: 29633304
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Survival in Hepatocellular Carcinoma Patients.
Gokcan H; Savaş N; Oztuna D; Moray G; Boyvat F; Haberal M
Ann Transplant; 2015 Oct; 20():596-603. PubMed ID: 26438974
[TBL] [Abstract][Full Text] [Related]
15. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
[TBL] [Abstract][Full Text] [Related]
16. Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center.
Grigorie R; Alexandrescu S; Smira G; Ionescu M; Hrehoreţ D; Braşoveanu V; Dima S; Ciurea S; Boeţi P; Dudus I; Picu N; Zamfir R; David L; Botea F; Gheorghe L; Tomescu D; Lupescu I; Boroş M; Grasu M; Dumitru R; Toma M; Croitoru A; Herlea V; Pechianu C; Năstase A; Popescu I
Chirurgia (Bucur); 2017; 112(3):289-300. PubMed ID: 28675364
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of liver cancer screening.
Cucchetti A; Cescon M; Erroi V; Pinna AD
Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):961-72. PubMed ID: 24182614
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of navigated radiofrequency ablation for hepatocellular carcinoma in China.
Lai Y; Li K; Li J; Liu SX
Int J Technol Assess Health Care; 2014 Oct; 30(4):400-8. PubMed ID: 25682956
[TBL] [Abstract][Full Text] [Related]
19. Financial Burden of Liver Transplant vs Resection for Hepatocellular Carcinoma.
Skill NJ; Butler J; O'Brien DC; Kays JK; Kubal CA; Liangpunsakul S; Ninad N; Maluccio MA
Transplant Proc; 2019; 51(6):1907-1912. PubMed ID: 31399174
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
